selected publications
-
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2024
Academic Article
GET IT
Times cited: 2 -
Quantitative Systems Toxicology Modeling Informed Safe Dose Selection of Emvododstat in Acute Myeloid Leukemia Patients.
Clinical pharmacology and therapeutics.
2023
Academic Article
GET IT
Times cited: 6 -
Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
Frontiers in oncology.
2022
Academic Article
GET IT
Times cited: 13 -
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent.
Molecular cancer therapeutics.
2021
Academic Article
GET IT
Times cited: 20 -
Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors.
Clinical pharmacology in drug development.
2021
Academic Article
GET IT
Times cited: 19 -
Ataluren treatment of patients with nonsense mutation dystrophinopathy.
Muscle & nerve.
2014
Academic Article
GET IT
Times cited: 370